F Dx Advisors, Inc. Gilead Sciences, Inc. Transaction History

F Dx Advisors, Inc.

$659 Million
Q1 2024

A detailed history of F Dx Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, F Dx Advisors, Inc. holds 5,839 shares of GILD stock, worth $388,819. This represents 0.06% of its overall portfolio holdings.

Number of Shares

5,839

Previous 6,149 5.04%

Holding current value

$388,819

Previous $498,000 14.06%

% of portfolio

0.06%

Previous 0.04%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$71.58 - $87.29 $22,189 - $27,059	-310 Reduced 5.04%	5,839 $428,000
Q4 2023 Feb 12, 2024	BUY	$73.27 - $83.09 $127,563 - $144,659	1,741 Added 39.5%	6,149 $498,000
Q3 2023 Nov 02, 2023	SELL	$73.94 - $80.67 $85,104 - $92,851	-1,151 Reduced 20.71%	4,408 $330,000
Q2 2023 Jul 17, 2023	SELL	$76.01 - $86.7 $545,751 - $622,506	-7,180 Reduced 56.36%	5,559 $428,000
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $267,789 - $384,452	-4,297 Reduced 25.22%	12,739 $1.09 Million

Q3 2022 Nov 10, 2022	SELL	$59.54 - $68.01 $122,235 - $139,624	-2,053 Reduced 10.75%	17,036 $1.05 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $165,483 - $186,383	2,867 Added 17.67%	19,089 $1.18 Million
Q1 2022 May 03, 2022	BUY	$57.92 - $72.58 $16,854 - $21,120	291 Added 1.83%	16,222 $964,000
Q4 2021 Feb 01, 2022	SELL	$64.88 - $73.64 $57,937 - $65,760	-893 Reduced 5.31%	15,931 $1.16 Million
Q3 2021 Oct 08, 2021	SELL	$67.69 - $73.03 $10,085 - $10,881	-149 Reduced 0.88%	16,824 $1.18 Million
Q2 2021 Aug 05, 2021	SELL	$63.47 - $69.35 $111,009 - $121,293	-1,749 Reduced 9.34%	16,973 $1.17 Million
Q1 2021 Apr 14, 2021	BUY	$60.0 - $68.46 $1.05 Million - $1.2 Million	17,512 Added 1447.27%	18,722 $1.21 Million
Q1 2021 Apr 13, 2021	SELL	$60.0 - $68.46 $908,760 - $1.04 Million	-15,146 Reduced 92.6%	1,210 $78,000
Q4 2020 Feb 08, 2021	BUY	$56.65 - $64.55 $203,656 - $232,057	3,595 Added 28.17%	16,356 $953,000
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $728,991 - $916,581	-11,739 Reduced 47.91%	12,761 $806,000
Q2 2020 Jul 22, 2020	BUY	$72.34 - $84.0 $600,132 - $696,864	8,296 Added 51.2%	24,500 $1.89 Million
Q1 2020 May 22, 2020	BUY	$62.63 - $80.22 $769,409 - $985,502	12,285 Added 313.47%	16,204 $1.21 Million
Q1 2020 May 13, 2020	SELL	$62.63 - $80.22 $653,857 - $837,496	-10,440 Reduced 72.71%	3,919 $388,000
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $201,559 - $221,708	-3,271 Reduced 18.55%	14,359 $933,000
Q3 2019 Nov 07, 2019	BUY	$62.51 - $69.0 $731,179 - $807,093	11,697 Added 197.15%	17,630 $1.12 Million
Q2 2019 Jul 19, 2019	SELL	$61.87 - $69.38 $17,385 - $19,495	-281 Reduced 4.52%	5,933 $401,000
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $16,632 - $18,633	-266 Reduced 4.1%	6,214 $404,000
Q4 2018 Apr 29, 2019	SELL	$60.54 - $79.0 $151,228 - $197,342	-2,498 Reduced 27.82%	6,480 $405,000
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $595,229 - $776,728	-9,832 Reduced 52.27%	8,978 $562,000
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $47,543 - $52,639	667 Added 3.68%	18,810 $1.45 Million
Q2 2018 Aug 08, 2018	SELL	$64.88 - $75.68 $1.86 Million - $2.17 Million	-28,632 Reduced 61.21%	18,143 $1.29 Million
Q1 2018 May 02, 2018	BUY	$72.84 - $88.8 $107,001 - $130,447	1,469 Added 3.24%	46,775 $3.53 Million
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $528,715 - $620,637	7,431 Added 19.62%	45,306 $3.25 Million
Q3 2017 Nov 03, 2017	BUY	$72.11 - $85.47 $386,076 - $457,606	5,354 Added 16.46%	37,875 $3.07 Million
Q2 2017 Aug 11, 2017	BUY	N/A	32,521	32,521 $2.3 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.5B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.

Account